Abbott Laboratories is back in focus after several research houses reset their price targets, with some cuts in the US$5 to US$29 range and at least one target lifted into the mid US$150s. Those moves ...
The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...
This company has delivered earnings and dividend growth over time. Abbott’s innovation and a new acquisition could spur more growth in the years to come. 10 stocks we like better than Abbott ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results